{"organizations": [], "uuid": "1528d332d54965d22f7fcb20cef0c7d15a6e964d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XR504_CELGEN_SOC_20180228182044.jpg", "site_section": "https://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "https://www.wsj.com/articles/can-celgene-save-itself-1519900201", "country": "US", "domain_rank": 387, "title": "Can Celgene Save Itself?", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.143, "site_type": "news", "published": "2018-03-01T13:30:00.000+02:00", "replies_count": 0, "uuid": "1528d332d54965d22f7fcb20cef0c7d15a6e964d"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/can-celgene-save-itself-1519900201", "ord_in_thread": 0, "title": "Can Celgene Save Itself?", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "celgene", "sentiment": "negative"}, {"name": "food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Celgene’s hard-won status as a biotech blue chip has unraveled in just months.\nThe latest blow came Tuesday when Celgene announced that the Food and Drug Administration took a rare step and declined to review Celgene’s application for its experimental multiple sclerosis drug, Ozanimod. Shares fell 9% in response on Wednesday. Drugs that receive such treatment often fail to ever reach the market; those that do often sell poorly.\nThat... ", "external_links": [], "published": "2018-03-01T13:30:00.000+02:00", "crawled": "2018-03-01T18:53:30.027+02:00", "highlightTitle": ""}